Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACA-S 2 in operable gastric adenocarcinoma
2010-021052-25Phase 3Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Aug 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, fluorouracil, oxaliplatin, epirubicin and capecitabine in gastric adenocarcinoma (4 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Overall survival and Locoregional relapse-free survival. Started Aug 2010; status: terminated.
02
Drugs
cisplatinfluorouraciloxaliplatinepirubicincapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2010-021052-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021052-25.